Jafron BiomedicalLtd Balance Sheet Health
Financial Health criteria checks 5/6
Jafron BiomedicalLtd has a total shareholder equity of CN¥3.2B and total debt of CN¥1.8B, which brings its debt-to-equity ratio to 55.5%. Its total assets and total liabilities are CN¥5.9B and CN¥2.6B respectively. Jafron BiomedicalLtd's EBIT is CN¥582.1M making its interest coverage ratio -22.2. It has cash and short-term investments of CN¥3.1B.
Key information
55.5%
Debt to equity ratio
CN¥1.80b
Debt
| Interest coverage ratio | -22.2x |
| Cash | CN¥3.14b |
| Equity | CN¥3.23b |
| Total liabilities | CN¥2.62b |
| Total assets | CN¥5.85b |
Recent financial health updates
Recent updates
Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40
May 28
A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
May 24Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge
May 08Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture
May 02Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital
Apr 13Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?
Mar 22Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce
Mar 04Financial Position Analysis
Short Term Liabilities: 300529's short term assets (CN¥3.6B) exceed its short term liabilities (CN¥1.2B).
Long Term Liabilities: 300529's short term assets (CN¥3.6B) exceed its long term liabilities (CN¥1.4B).
Debt to Equity History and Analysis
Debt Level: 300529 has more cash than its total debt.
Reducing Debt: 300529's debt to equity ratio has increased from 0% to 55.5% over the past 5 years.
Debt Coverage: 300529's debt is well covered by operating cash flow (66%).
Interest Coverage: 300529 earns more interest than it pays, so coverage of interest payments is not a concern.